We are leveraging our R&D Engine to develop a pipeline of product candidates with a high probability of success in immuno-oncology, neurosciences, and rare diseases. By focusing on clinical candidates with a plethora of human patient data, we believe that our approach will result in designing efficient clinical trials and rapidly achieving human proof-of-concept.

Our clinical pipeline is being developed by BioXcel Therapuetics, Inc.

We will continue to use our R&D Engine to create a robust de-risk product portfolio across oncology, neuroscience & rare diseases.

De-Risked Clinical Portfolio